Tirzepatide's benefits fade for most: Weight and health markers rebound after withdrawal, study finds

Eli Lilly and Company, along with partner institutions in the US and United Kingdom, describe how short-term pharmacologic intervention does not appear to have lasting effects for most tirzepatide patients. People with obesity who lost weight on…

Continue Reading

News Source: medicalxpress.com